泰伦那班

泰伦那班
临床资料
给药途径	口服
ATC码	A08AX (WHO) ;
法律规范状态
法律规范	实验性（失败）;
识别信息
	IUPAC命名法 N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide; ;
CAS号	701977-09-5
PubChem CID	11226090;
ChemSpider	9401143;
UNII	X9U622S114;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID60220464 ;
ECHA InfoCard	100.207.983
化学信息
化学式	C27H25ClF3N3O2
摩尔质量	515.96 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F;
	InChI InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1; Key:QLYKJCMUNUWAGO-GAJHUEQPSA-N;

泰伦那班（英语：Taranabant；研发代号：MK-0364）是一种大麻素受体1反向激动剂，由于其厌食作用而被研究作为一种潜在的肥胖治疗方法。^[1]^[2]它是由默克公司发现的。

2008年10月，由于中枢神经系统的严重副作用（主要是抑郁和焦虑），默克公司停止了该药物的III期临床试验。^[3]^[4]^[5]^[6]

参见

大麻素受体拮抗剂

参考资料

^ Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK; et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Bioorganic & Medicinal Chemistry Letters. 2007, 17 (8): 2184–7. PMID 17293109. doi:10.1016/j.bmcl.2007.01.087.
^ Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics. Jun 2007, 321 (3): 1013–22. PMID 17327489. S2CID 20001781. doi:10.1124/jpet.106.118737.
^ Press release by Merck. [4 October 2008]. （原始内容存档于2009-09-21）.
^ Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. International Journal of Obesity. May 2010, 34 (5): 919–35. PMID 20157323. doi:10.1038/ijo.2010.21  .
^ Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes, Obesity & Metabolism. June 2010, 12 (6): 517–31. PMID 20518807. S2CID 23886192. doi:10.1111/j.1463-1326.2009.01188.x  .
^ Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity. August 2010, 34 (8): 1243–54. PMID 20212496. doi:10.1038/ijo.2010.38  .

[1] Armstrong HE, Galka A, Lin LS, Lanza TJ Jr, Jewell JP, Shah SK; et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. Bioorganic & Medicinal Chemistry Letters. 2007, 17 (8): 2184–7. PMID 17293109. doi:10.1016/j.bmcl.2007.01.087.

[2] Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. Journal of Pharmacology and Experimental Therapeutics. Jun 2007, 321 (3): 1013–22. PMID 17327489. S2CID 20001781. doi:10.1124/jpet.106.118737.

[urlMerck_News_Item-3] Press release by Merck. [4 October 2008]. （原始内容存档于2009-09-21）.

[pmid20157323-4] Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. International Journal of Obesity. May 2010, 34 (5): 919–35. PMID 20157323. doi:10.1038/ijo.2010.21  .

[pmid20518807-5] Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes, Obesity & Metabolism. June 2010, 12 (6): 517–31. PMID 20518807. S2CID 23886192. doi:10.1111/j.1463-1326.2009.01188.x  .

[pmid20212496-6] Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity. August 2010, 34 (8): 1243–54. PMID 20212496. doi:10.1038/ijo.2010.38  .

[1]

[2]

[3]

[4]

[5]

[6]